Fate Therapeutics announced promising preliminary clinical trial results for FT819, an investigational CAR T-cell therapy for ...

A new pooled analysis of adults with systemic lupus erythematosus (SLE) found commonly used patient-reported measures varied meaningfully in sensitivity to clinical changes in SLE, disease course and ...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to EG-501 from Evergreen Therapeutics, an investigational oral treatment for adults with cognitive impairment associated ...

A new study found that dietary supplement use is widespread among adults living with systemic lupus erythematosus (SLE), with more than 80% of participants reporting use of at least one supplement and ...

Beginning in September, people living with lupus, along with their families and friends, advocates, supporters and community leaders will come together for the Lupus Foundation of America’s (LFA) 2026 ...

Novartis and Bristol Myers Squibb have paused their clinical trials studying their respective CAR-T cell therapies for lupus and other autoimmune diseases while they review safety findings. Novartis ...

June is Men’s Health Month, a time to shine light on the health challenges that affect men with lupus and encourage open, honest conversations about care and well-being. For the lupus community, this ...

The U.S. Food & Drug Administration (FDA) has granted approval for subcutaneous administration of anifrolumab (SAPHNELO) for treatment of people living with moderately to severely active ...

The Lupus Foundation of America's National Lupus Advocacy Summit brings together the entire lupus community to urge members of Congress to support policies that will help people living with lupus.

The U.S. Food and Drug Administration (FDA) has granted Johnson & Johnson’s, nipocalimab, Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE). This ...

A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in people with progressive and treatment-resistant systemic sclerosis (SSc), ...

In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen autoimmune skin conditions, such as in people with cutaneous lupus erythematosus ...